Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Idea Of The Day -- Ignore unavailable to you. Want to Upgrade?

To: IQBAL LATIF who wrote (16469)	1/18/1998
From: Henry Niman	Respond to of 50167

IQBAL, I'm more familiar with Type II than Type I. For Type I, AMLN is trying to get Pramlintide approved. They had modest success on their first Phase III trials, but their type II data left much to be desired, so they are doing 4 more trials. Pramlintide is a sythetic analog of the hormone Amylin which is made by the same pancreatic cells that make insulin. It is thought that Amylin will smoothen out the glucose levels which can get out of control and lead to serious consequnces. There are also attemts to give insulin via spray or capsule that protect the protein from destruction by stomach enzymes. I believe that there is also research ongoing concern pancreas transplants, but all of the above are really out of my area.